Cathy Schnabel | Board Member
Chief Scientific Officer, Biotheranostics, Inc.
Catherine Schnabel is a biotechnology and life sciences executive with a record of achievement in scientific and medical strategy, clinical development, scientific leadership and translational research. Throughout her professional life, Cathy has been committed to pursuing cutting edge science that will lead to better outcomes and healthcare for patients. Driven by innovation, her experience was developed within industry-leading biotechnology companies such as Genentech, Genoptix and Amylin Pharmaceuticals, researching first-in-class therapies and technologies.
Currently serving as the Chief Scientific Officer of Biotheranostics Inc., Cathy played a significant role in leading the company from a research-based organization to a commercial entity, and her broad oversight includes R & D, Medical Affairs, Regulatory Affairs, and Clinical Development. Towards the goal of personalizing cancer treatment and precision medicine, Biotheranostics provides advanced diagnostics that help individualize treatment choices based on the particular tumor biology and molecular background of each patient. Trained as a molecular biologist and an author of many publications and patents, her leadership was critical to translating biomarkers to products that have been incorporated into National and International Clinical Practice Guidelines, and that changes lives every day for cancer patients.
Cathy received her Ph.D. training in molecular and cellular biology at the Center for Advanced Biotechnology and Medicine, and was a postdoctoral fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University. She has broad expertise in both the pharmaceutical and diagnostic arenas with knowledge spanning research, product development and commercialization. She has been nominated for the Athena Pinnacle Award in the Life Sciences and the Women Who Mean Business Award from the San Diego Business Journal.